Rituximab induced lung injury
Abstract Background Rituximab is a chimeric human-mouse immunoglobulin monoclonal antibody with high affinity for CD20 surface antigens expressed by pre-B and B cells that is commonly used as the mainstay for the treatment of B cell non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma (D...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2025-07-01
|
| Saila: | BMC Pulmonary Medicine |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12890-025-03802-x |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|